Poly(ADP-ribose) polymerase inhibition in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with limited treatment options. Recently, the poly(ADP-ribose) polymerase inhibitor (PARPi) olaparib has been approved for maintenance therapy after successful platinum-based chemotherapy in patients with germline mutations in BRCA1 and BRC...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Singh, Hans Martin (VerfasserIn) , Bailey, Peter (VerfasserIn) , Hübschmann, Daniel (VerfasserIn) , Berger, Anne Katrin (VerfasserIn) , Neoptolemos, John P. (VerfasserIn) , Jäger, Dirk (VerfasserIn) , Siveke, Jens (VerfasserIn) , Springfeld, Christoph (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2021
In: Genes, chromosomes & cancer
Year: 2021, Jahrgang: 60, Heft: 5, Pages: 373-384
ISSN:1098-2264
DOI:10.1002/gcc.22932
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1002/gcc.22932
Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/gcc.22932
Volltext
Verfasserangaben:Hans Martin Singh, Peter Bailey, Daniel Hübschmann, Anne Katrin Berger, John P. Neoptolemos, Dirk Jäger, Jens Siveke, Christoph Springfeld

MARC

LEADER 00000caa a2200000 c 4500
001 1779786387
003 DE-627
005 20220208210714.0
007 cr uuu---uuuuu
008 211129s2021 xx |||||o 00| ||eng c
024 7 |a 10.1002/gcc.22932  |2 doi 
035 |a (DE-627)1779786387 
035 |a (DE-599)KXP1779786387 
035 |a (OCoLC)1295678388 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Singh, Hans Martin  |d 1986-  |e VerfasserIn  |0 (DE-588)1077055021  |0 (DE-627)835896986  |0 (DE-576)445904542  |4 aut 
245 1 0 |a Poly(ADP-ribose) polymerase inhibition in pancreatic cancer  |c Hans Martin Singh, Peter Bailey, Daniel Hübschmann, Anne Katrin Berger, John P. Neoptolemos, Dirk Jäger, Jens Siveke, Christoph Springfeld 
264 1 |c 2021 
300 |a 12 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a First published: 20 December 2020 
500 |a Gesehen am 29.11.2021 
520 |a Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with limited treatment options. Recently, the poly(ADP-ribose) polymerase inhibitor (PARPi) olaparib has been approved for maintenance therapy after successful platinum-based chemotherapy in patients with germline mutations in BRCA1 and BRCA2. Approval was based on the POLO study that has shown a significant improvement in progression-free survival for patients with metastatic PDAC after at least 4 months of platinum-based chemotherapy. Hopefully, this first biomarker-directed targeted therapy for a relevant subgroup of pancreatic cancer patients is only the beginning of an era of personalized therapy for pancreatic cancer. The potential role for PARPi in improving survival in patients with pancreatic cancer containing somatic tumor mutations has yet to be established. Multiple studies investigating whether PARPi therapy might benefit a larger group of pancreatic cancer patients with homologous recombination repair deficiency and whether combinations with chemotherapy, immunotherapy, or small molecules can improve efficacy are currently underway. We here review the molecular basis for PARPi therapy in PDAC patients and recent developments in clinical studies. 
650 4 |a olaparib 
650 4 |a pancreatic cancer 
650 4 |a PARP inhibitor 
700 1 |a Bailey, Peter  |e VerfasserIn  |4 aut 
700 1 |a Hübschmann, Daniel  |d 1981-  |e VerfasserIn  |0 (DE-588)1099133653  |0 (DE-627)858143798  |0 (DE-576)469237082  |4 aut 
700 1 |a Berger, Anne Katrin  |d 1978-  |e VerfasserIn  |0 (DE-588)132177889  |0 (DE-627)519022424  |0 (DE-576)298988380  |4 aut 
700 1 |a Neoptolemos, John P.  |e VerfasserIn  |0 (DE-588)172283302  |0 (DE-627)697192954  |0 (DE-576)133150879  |4 aut 
700 1 |a Jäger, Dirk  |d 1964-  |e VerfasserIn  |0 (DE-588)1032507535  |0 (DE-627)738505323  |0 (DE-576)380074125  |4 aut 
700 1 |a Siveke, Jens  |e VerfasserIn  |4 aut 
700 1 |a Springfeld, Christoph  |d 1972-  |e VerfasserIn  |0 (DE-588)123388910  |0 (DE-627)706281039  |0 (DE-576)293689385  |4 aut 
773 0 8 |i Enthalten in  |t Genes, chromosomes & cancer  |d New York, NY : Wiley-Liss, 1989  |g 60(2021), 5, Seite 373-384  |h Online-Ressource  |w (DE-627)302922369  |w (DE-600)1492641-6  |w (DE-576)094400474  |x 1098-2264  |7 nnas  |a Poly(ADP-ribose) polymerase inhibition in pancreatic cancer 
773 1 8 |g volume:60  |g year:2021  |g number:5  |g pages:373-384  |g extent:12  |a Poly(ADP-ribose) polymerase inhibition in pancreatic cancer 
856 4 0 |u https://doi.org/10.1002/gcc.22932  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u https://onlinelibrary.wiley.com/doi/abs/10.1002/gcc.22932  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20211129 
993 |a Article 
994 |a 2021 
998 |g 123388910  |a Springfeld, Christoph  |m 123388910:Springfeld, Christoph  |d 910000  |d 910100  |d 50000  |e 910000PS123388910  |e 910100PS123388910  |e 50000PS123388910  |k 0/910000/  |k 1/910000/910100/  |k 0/50000/  |p 8  |y j 
998 |g 1032507535  |a Jäger, Dirk  |m 1032507535:Jäger, Dirk  |d 910000  |e 910000PJ1032507535  |k 0/910000/  |p 6 
998 |g 172283302  |a Neoptolemos, John P.  |m 172283302:Neoptolemos, John P.  |d 910000  |d 910200  |e 910000PN172283302  |e 910200PN172283302  |k 0/910000/  |k 1/910000/910200/  |p 5 
998 |g 132177889  |a Berger, Anne Katrin  |m 132177889:Berger, Anne Katrin  |d 910000  |d 910100  |d 50000  |e 910000PB132177889  |e 910100PB132177889  |e 50000PB132177889  |k 0/910000/  |k 1/910000/910100/  |k 0/50000/  |p 4 
998 |g 1099133653  |a Hübschmann, Daniel  |m 1099133653:Hübschmann, Daniel  |d 910000  |d 910500  |e 910000PH1099133653  |e 910500PH1099133653  |k 0/910000/  |k 1/910000/910500/  |p 3 
998 |g 1077055021  |a Singh, Hans Martin  |m 1077055021:Singh, Hans Martin  |d 910000  |d 910100  |e 910000PS1077055021  |e 910100PS1077055021  |k 0/910000/  |k 1/910000/910100/  |p 1  |x j 
999 |a KXP-PPN1779786387  |e 4008891773 
BIB |a Y 
SER |a journal 
JSO |a {"origin":[{"dateIssuedKey":"2021","dateIssuedDisp":"2021"}],"note":["First published: 20 December 2020","Gesehen am 29.11.2021"],"title":[{"title":"Poly(ADP-ribose) polymerase inhibition in pancreatic cancer","title_sort":"Poly(ADP-ribose) polymerase inhibition in pancreatic cancer"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"recId":"1779786387","relHost":[{"pubHistory":["1.1989/90 -"],"origin":[{"publisherPlace":"New York, NY","dateIssuedKey":"1989","publisher":"Wiley-Liss","dateIssuedDisp":"1989-"}],"note":["Gesehen am 14.12.07"],"title":[{"title":"Genes, chromosomes & cancer","title_sort":"Genes, chromosomes & cancer"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Poly(ADP-ribose) polymerase inhibition in pancreatic cancerGenes, chromosomes & cancer","recId":"302922369","physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["302922369"],"doi":["10.1002/(ISSN)1098-2264"],"issn":["1098-2264"],"zdb":["1492641-6"]},"language":["eng"],"part":{"text":"60(2021), 5, Seite 373-384","issue":"5","year":"2021","pages":"373-384","volume":"60","extent":"12"}}],"name":{"displayForm":["Hans Martin Singh, Peter Bailey, Daniel Hübschmann, Anne Katrin Berger, John P. Neoptolemos, Dirk Jäger, Jens Siveke, Christoph Springfeld"]},"physDesc":[{"extent":"12 S."}],"id":{"eki":["1779786387"],"doi":["10.1002/gcc.22932"]},"person":[{"given":"Hans Martin","role":"aut","family":"Singh","display":"Singh, Hans Martin"},{"role":"aut","given":"Peter","family":"Bailey","display":"Bailey, Peter"},{"family":"Hübschmann","display":"Hübschmann, Daniel","given":"Daniel","role":"aut"},{"display":"Berger, Anne Katrin","family":"Berger","role":"aut","given":"Anne Katrin"},{"display":"Neoptolemos, John P.","family":"Neoptolemos","given":"John P.","role":"aut"},{"family":"Jäger","display":"Jäger, Dirk","given":"Dirk","role":"aut"},{"family":"Siveke","display":"Siveke, Jens","role":"aut","given":"Jens"},{"family":"Springfeld","display":"Springfeld, Christoph","given":"Christoph","role":"aut"}],"language":["eng"]} 
SRT |a SINGHHANSMPOLYADPRIB2021